← Back to Search

Peripheral Nerve Ultrasound for Guillain-Barre Syndrome

N/A

Waitlist Available

Led By Lisa Hobson-Webb, M.D.

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

For control group: Hospitalized patients on the inpatient neurology service who are being treated for non-peripheral nerve disorders (e.g. epilepsy, multiple sclerosis, or stroke).

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 7 days after admission

Awards & highlights

Study Summary

This trial will help determine if using ultrasound to scan for Guillain-Barre syndrome is effective and can help with predicting the course of the disease.

Who is the study for?

This trial is for adults over 18 who are hospitalized with sudden weakness and suspected Guillain-Barre syndrome (GBS), without a clear alternative diagnosis, and whose symptoms started within the last month. A control group includes inpatients treated for neurological conditions other than peripheral nerve disorders.Check my eligibility

What is being tested?

The study is testing if ultrasound scans of peripheral nerves can help diagnose GBS quickly and predict outcomes. It involves comparing these ultrasounds from patients with suspected GBS to those from patients with other neurological issues.See study design

What are the potential side effects?

Since this trial uses non-invasive ultrasound imaging and strength measurements, there are minimal risks involved. Side effects might include discomfort during the scan or anxiety about test results.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am hospitalized for a brain or spinal cord condition, not related to nerve damage.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 7 days after admission

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 7 days after admission

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 7 days after admission for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Guillain-Barre Syndrome

Internerve variability of cross-sectional area (CSA) in patients with GBS vs controls at Day 0

Median nerve CSA variability in patients with GBS vs controls at Day 0

+3 more

Secondary outcome measures

Value of peripheral nerve ultrasound in prediction of disability in patients with GBS at 3 months.

Value of peripheral nerve ultrasound in prediction of disability in patients with GBS at 6 months.

Value of peripheral nerve ultrasound in prediction of disability in patients with GBS at Day 0

+12 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: GBS PatientsExperimental Treatment2 Interventions

Group II: ControlsActive Control1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

GBS-CIDP foundationUNKNOWN

Duke UniversityLead Sponsor

2,359 Previous Clinical Trials

3,420,172 Total Patients Enrolled

Lisa Hobson-Webb, M.D.Principal InvestigatorDuke University

Media Library

Measurement of strength Clinical Trial Eligibility Overview. Trial Name: NCT04053452 — N/A

Guillain-Barre Syndrome Research Study Groups: Controls, GBS Patients

Guillain-Barre Syndrome Clinical Trial 2023: Measurement of strength Highlights & Side Effects. Trial Name: NCT04053452 — N/A

Measurement of strength 2023 Treatment Timeline for Medical Study. Trial Name: NCT04053452 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What objectives does this medical experiment hope to fulfill?

"This clinical trial will be assessed for approximately 7 days after admittance. The primary outcome aims to evaluate Ulnar nerve CSA variability in GBS patients versus controls at Day 7. Secondary objectives include measuring the value of peripheral nerve ultrasound when predicting disability, autonomic dysfunction, and ambulation status upon discharge as measured by GBS Disability Score, chart review on presence/absence of Autonomic Dysfunction (AD) and Ambulatory Status (AS). Peripheral nerve ultrasounds measure internerve and intranerve CSA of Median Nerve, Ulnar Nerve, Vagus Nerve, C6 & C7 Root nerves respectively"

Answered by AI

Are there any slots open for participants in this clinical trial?

"Clinicaltrials.gov's data states that this trial, first made public on September 30th 2019 and last updated on the twentieth of September in 2022, is not currently recruiting patients. However, there are over 1300 different medical studies presently seeking applicants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome

2019. "Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04053452.